We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Erythropoietin Found to Boost Higher Brain Functions

By HospiMedica International staff writers
Posted on 30 Jul 2009
Erythropoietin, a human growth factor, improves the sequential learning and memory components of a complex long-term cognitive task, according to a new study. More...


Researchers at the Max Planck Institute of Experimental Medicine (Göttingen, Germany) tested the effects of erythropoietin as manifested in the ability of male mice to learn how to exploit an experimental setup developed to supply them with sugared water. The mice were treated for 3 weeks with erythropoietin (5,000 IU/kg) versus placebo administered intraperitoneally every other day, beginning at postnatal day 28. After termination of treatment, the mice were started on the Five Choice Serial Reaction Time Task, with daily training and testing extending to about three months; over a series of learning stages, the mice were trained to operate the system by poking their noses into holes lit by light emitting diodes (LEDs), rather than into unlit holes, within a certain time limit.

The researchers found that overall, a significantly higher proportion of erythropoietin-treated mice finished the task, reaching the predetermined criteria of adequately reacting to a one second flash light, out of five arbitrarily appearing choices. During acquisition of this capability, and over almost all sequential training phases, learning readouts were superior in the erythropoietin-treated mice. The study was published in the July 8, 2009, edition of the open access journal BMC Biology, a publication of BioMedCentral.

"Treated mice showed superior performance in associative, operant and discriminate learning as well as in the initial training phases. Moreover, erythropoietin-treated mice demonstrated better task adaptation and higher performance stability,” said lead author Hannelore Ehrenreich, M.D., D.V.M. "Further untangling of molecular mechanisms of erythropoietin action on higher cognitive functions may ultimately open new avenues for prevention strategies and therapeutic interventions in neuropsychiatric diseases.”

Erythropoietin is a glycoprotein hormone that controls erythropoiesis, or red blood cell (RBC) production. It is produced by the peritubular capillary endothelial cells in the kidney, and has other known biological functions: for example, erythropoietin plays an important role in the brain's response to neuronal injury, and is also involved in the wound healing process. Erythropoietin has been used for over 20 years to treat patients with anemic conditions, ranging from renal failure to cancer, and has recently received attention for its apparent ability to improve cognitive function in people with schizophrenia and multiple sclerosis.

Related Links:

Max Planck Institute of Experimental Medicine
BioMedCentral




New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
12-Channel ECG
CM1200B
New
Wound Irrigation Solution
Prontosan®
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.